Dr Jack Tan
President of Asian Pacific Society of Cardiology

APAC Heart Failure Gap Report


  • Continued research is needed to address many gaps prevalent in the management of Heart Failure such as going beyond traditional tools for HF risk prediction in high risk patients.
  • There is a need for high value methods for the biomarker use in optimization of HF therapy.
  • Advanced role of precision medicine such as genetics, personalized and individualized factors for the medical management of HF patients.

Dr Jack Tan shares some of the salient findings from the APAC HF gap report project and the highlights of the consensus statement developed.

Disclaimer: The platforms may include third-party content (including data and information) and that Roche will not be responsible for third-party materials, including their accuracy, completeness and validity.

Updates from Leading Experts

STRONG-HF: Post-discharge Heart Failure Management and Implementation of GDMT Heart Failure Therapy

Prof Alexandre Mebazaa shares the key results and highlights from the STRONG-HF study that assessed the safety, tolerability of optimization of guideline directed medical therapy. [...]


CANVAS study: NT-proBNP and CVD risk reduction

Can you give us a short description of the CANVAS program? The CANVAS program was a set of two trials, whose goal was to evaluate the role of an SGLT2...

1 July 2021
Dr James L Januzzi